RLAY
RLAY
NASDAQ · Biotechnology

Relay Therapeutics Inc

$15.88
+0.32 (+2.06%)
As of Jun 21, 10:07 PM ET ·
Financial Highlights (FY 2026)
Revenue
19.88M
Net Income
-357,929,124
Gross Margin
Profit Margin
-1,800.6%
Rev Growth
+123.3%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 61.2% 61.2%
Operating Margin -1,971.6% -3,349.9% 34.0% 31.7%
Profit Margin -1,800.6% -3,206.0% 20.5% 21.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 19.88M 8.30M 220.69M 215.28M
Gross Profit 135.02M 131.71M
Operating Income -391,976,717 -277,933,692 75.10M 68.21M
Net Income -357,929,124 -252,156,044 45.13M 45.09M
Gross Margin 61.2% 61.2%
Operating Margin -1,971.6% -3,349.9% 34.0% 31.7%
Profit Margin -1,800.6% -3,206.0% 20.5% 21.0%
Rev Growth +123.3% +48.9% +11.7% +6.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 477.64M 487.30M
Total Equity 867.00M 902.73M
D/E Ratio 0.55 0.54
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -387,317,831 -289,236,526 96.01M 91.95M
Free Cash Flow 41.24M 69.53M